BIOCHEMICAL
Vol. 169, No. 3, 1990
AND BIOPHYSICAL RESEARCH COMMUNICATIONS Pages 1158-l 163
June 29, 1990
REACTION
OF AUTOXIDATION PRODUCTS WITH MYELOPEROXIDASE Leah A. Marquez
OF PENICILLAMINE
and H. Brian Dunford
Department of Chemistry, University of Alberta Edmonton, Alberta, Canada T6G 2G2 Received
May 18,
1990
SUMMARY: Spectral evidence is presented which shows that penicillamine is able to initiate the formation of the oxidized intermediates of myeloperoxidase in the absence of exogenous hydrogen peroxide. The autoxidation of penicillamine presumably produces superoxide which dismutates spontaneously to form hydrogen peroxide. Thus, the formation of both compounds II and Ill of myeloperoxidase was observed. We also report that penicillamine can directly reduce cytochrome c and therefore, it could possibly act as a one-electron donor to myeloperoxidase. 01990
Academic
Press,
Inc.
Penicillamine rheumatoid
(8,8-dimethylcysteine)
used
arthritis and a wide range of other human diseases
still remains
obscure.
Several
(2-4). More
recently,
studies
neutrophit
investigations were
myeloperoxidase
penicillamine interaction
on the
system
chlorinating
have focused
performed
(5-6).While
could
autoxidize
these
oxidation
reactions
adverse
effects (7) which
We report
penicillamine
was not studied.
here
Moreover,
hydrogen
the first evidence
its mode of action
investigated
in the presence For example,
peroxide
the use of penicillamine
for the interaction
of
function
of the drug with the human
studies
could be due to some reactions
with myeloperoxidase
treatment
on its effect on leucocyte
ability of myeloperoxidase
to form enough
for the
(1). However,
on the interaction
of the enzyme with the drug itself was not explored.
penicillamine
drug.
is extensively
mediated
the effect
of H202,
of
the
the possibility
that
to drive its own enzymatic has been linked to some by free radicals
of the autoxidation
from the
products
of
from bovine spleen.
MATERIALS AND METHODS Bovine spleen myeloperoxidase was prepared as described previously (8-10). The RZ ) of the samples used in this study was 0.82 or greater. The concentration nm’A 280 nm
tA430 of the enzyme was calculated using a molar absorptivity of 178 mM-t cm-l at 430 nm (I 1). Crystalline superoxide dismutase and catalase were obtained from Sigma Chemical Co St Louis, .-I at USA). The concentrations were calculated using molar absorptivities of 15.9 mM 4 cm 265 nm for superoxide dismutase (12) and 3.24 x 105 M“ cm-’ at 405 nm for catalase (13). Cytochrome c (horse heart) and D-penicillamine were also purchased from Sigma. Aqueous solutions of D-penicillamine were always freshly prepared. Hydrogen peroxide (30%) was obtained from BDH Chemicals and the concentration of diluted solutions were determined spectrophotometrically using a molar absorptivity of 39.4 M-l cm“ at 240 nm (14). 0006-291X/90 Copyrighr All rights
$1.50
0 1990 by Academic Press, Inc. of reproduction in any form reserved.
1158
Vol.
BIOCHEMICAL
169, No. 3, 1990
AND BIOPHYSICAL
RESEARCH COMMUNICATIONS
Spectrophotometric measurements were made on a Cary 219 spectrophotometer equipped with thermostatted cuvette holders. All experiments were performed at 25.0 + 0.5 OC and ionic strength of 0.1 M due to the contribution of phosphate buffer, pH 7.2. The anaerobic experiments were performed in cuvettes sealed with rubber caps. Solutions were made anaerobic by flushing for 20 minutes with nitrogen (Linde, Union Carbide) purified by passage through an oxygen trap (Oxiclear, Dow Chemical Co.). RESULTS Figure 1 depicts what happens D-penicillamine
without
the enzyme compound
exogenous
was converted II or compound
hydrogen
penicillamine, absorbance
the Soret maximum
of catalytic
sharper
(Fig.
28).
peak
myeloperoxidase-penicillamine incompletely
which
of superoxide
of myeloperoxidase
both
to distinguish
as
back to the native state
of compound
and a large excess of
nm was shifted
II (Fig. 2A). This intermediate dismutase
catalytic amounts
of native myeloperoxidase
to its oxidized
to 455
nm, the
was found to be of catalase
were
intermediate
as
430 nm and the formation
of a shoulder
at about
that the peak at 625 nm (characteristic
of compound
III) is
superoxide
were
system,
dismutase
compound
(Fig. 2C). All of the above experiments
and
II formation
catalase
still occurred
were performed
added
to the
albeit slowly
in the presence
Reaction of penicillamine with bovine spleen myeloperoxidase. Spectrum A was obtained by putting 0.75 pM myeloperoxidase in 0.1 M phosphate buffer at pH 7.2. Spectrum B was obtained after adding 25 eq of penicillamine to the reaction mixture in A. Each scan period is 3 min 30 s. 1159
and
of oxygen.
Wavelength (nm) Fig. 1.
of
period of 3 min 30 s
is hard
dismutase
at 430
If instead of superoxide
it is noticeable When
intermediate(s)
amounts
by the peak that still persists at around
450 nm. However,
Within a scanning
upon the addition
points (spectra not shown).
added, there is only partial conversion shown
myeloperoxidase
III. The decay spectra of the intermediate(s)
characteristic
stable for several minutes.
peroxide.
to (an) oxidized
did not show a single set of isosbestic In the presence
to native spleen
BIOCHEMICAL
Vol. 169, No. 3, 1990
AND BIOPHYSICAL
RESEARCH COMMUNICATIONS
0.16
A
1
g
0.10
C
x 5
r”
2
c
0.04
L
+
I 400
I 500
Wavelength
I 600
i
I
I
" 400
500
I
600
Wavelength
(nm)
(nm)
C
i; i ‘00
Wavelength
(nm)
Fig. 2. Effects of superoxide dismutase and catalase on the reaction of penicillamine with myeloperoxidase. A) To 0.75 pM myeloperoxidase in 0.1 M phosphate buffer at pH 7.2 was added 70 nM superoxide dismutase. B) Same conditions as A) except that 20 nM catalase was added instead of superoxide dismutase. C) Both superoxide dismutase (70 nM) and catalase (20 nM) were added to 0.75 pM myeloperoxfdase in 0.1 M phosphate buffer at pH 7.2. The succeeding spectral scans for all cases were taken 3 min 30 s of each other after addition of 75 uM penicillamine. The arrows indicate the direction of absorbance changes with increasing time.
When reaction
the addition was observed
of penicillamine (spectra
to myeloperoxidase
was carried
out anaerobicallly
no
not shown).
The effect of penicillamine native enzyme was also investigated
on compound
II formed
by adding
under both aerobic and anaerobic 1160
hydrogen
conditions.
peroxide
In the
to
Vol.
169,
No.
3, 1990
BIOCHEMICAL
AND
I 600
700
BIOPHYSICAL
RESEARCH
COMMUNICATIONS
0.06 8 cs 1 0.04 Q 0.02
0
3
I 400
I 500
Wavelength
4
I
,
I
400
500
600
Wavelength
(nm)
(nm)
Fig. 3. Effect of penicillamine on the rate of decay of myeloperoxidase compound II to native enzyme. To 0.5 uM myeloperoxidase was added 100 u-M penicillamine. Compound II was formed by adding 10 KM’ H202 to the reaction mixture under A) aerobic and B) anaerobic conditions. The arrows indicate the direction of absorbance changes with time.
I ’ Al 500 Wavelength
I
I
550
600
(nm)
Fig. 4. Reduction of cytochrome c by penicillamine. The initial reaction mixture contained 5 PM ferric cytochrome c to which 250 pM penicillamine was added. The same spectral changes were observed under aerobic conditions, anaerobic conditions and aerobic conditions in the presence of 0.10 uhf superoxide dismutase. The spectral scans were taken 4 min 30 s after each other; the arrows indicate direction of absorbance changes with increasing time. 1161
700
Vol.
BIOCHEMICAL
169, No. 3, 1990
presence
of oxygen,
compound
II undergoes
3A). On the other hand, when oxygen faster
RESEARCH COMMUNICATIONS
normal spontaneous
is absent, the reversion
decay to the native state (Fig. of compound
II to native form is
(Fig. 38). To explore
further
form of cytochrome reduced
dismutase
ability of penicillamine,
Upon addition
by the increase
c was observed
superoxide
the reducing
c was studied.
as shown
cytochrome (Fig.
AND BIOPHYSICAL
of penicillamine
in the intensity
under both aerobic
its reaction to cytochrome
of the peak
and anaerobic
was added to the system, cytochrome
with the oxidized c, the latter was
at 550
conditions.
nm. Reduction
Moreover,
c was still reduced
of
even when
by penicillamine
4). DlscussloN The
oxidizing
results
equivalents
of exogenous
presented
peroxide,
(Fig. 1). The concentration
radical
II in the presence mixture
and the hydrogen
peroxide
able
intermediate(s)
found in the blood samples autoxidizes
formed
to form a thiyl
to form compound can then oxidize
The spectra of the oxidized
II and III (Fig. 1). The presence
species thus appear
of more than one intermediate
was added,
II was obtained
stable (Fig. ZA), presumably instead of superoxide
because
dismutase,
dismutation
superoxide
dismutase
and catalase
2C). It can be inferred rapidly dismutated acted
upon by catalase
02-’
compound
is faster and thus more H202
dismutase II was more is formed.
formed
inhibit the formation from the autoxidation
oxidizes
penicillamine
If
Ill is formed as indicated by
which reacts with the enzyme to form compound
to form O2 which
is also
of a peak at 455 nm (Fig. 28). The presence
did not completely
that whatever
to H202
and the resultant
catalase was added, more compound
the sharper peak at 625 nm and the absence
the native
to be that of a
point in the decay spectra. When superoxide
yield of compound
Ill or it
I is also formed but rapidly decays to compound
verified by the lack of a single isosbestic a greater
to provide
In the absence
to its oxidized
with the drug (15). Penicillamine
of excess H202,
of compounds
is converted
used was that normally
II. Most probably compound
iS
by myeloperoxidase.
can react directly with myeloperoxidase
spontaneously
enzyme to compound
that penicillamine
catalyzed
myeloperoxidase
treated 02“
indicate
reactions
of penicillamine
patients
and superoxide.
can dismutate
clearly
to initiate oxidation
hydrogen
from rheumatoid
here
of compound
of both II (Fig.
of penicillamine
is
II. Excess H202 is
and the cycle of reactions
continues. AS
if penicillamine
expected
is added after compound
but in the absence absence
from the above mechanism,
acts
as a one-electron
and the thiyl radical while in the presence state concentration
II formation,
of 02 the decay of compound
of 02 penicillamine
H202
necessary
in the absence of 02, no reaction takes place. compound
if 0,
II to native state is hastened. donor to compound
of 02. autoxidation
lt.
is present
Possibly,
in the
II to form native enzyme
of penicillamine
for the formation of compound 1162
lt is stabilized
leads to a steady
Vol.
169, No. 3, 1990
BIOCHEMICAL
The fact that penicillamine ability to reduce
ferric cytochrome
agent in the system.
is capable
of superoxide
reduced
by penicillamine.
of acting as a one-electron
c. It is therefore
Even in the absence
presence
AND BIOPHYSICAL RESEARCH COMMUNICATIONS
dismutase
not only 02-m capable
of 02 (where
( which
dismutates
second,
first, penicillamine penicillamine
may directly
then reacts with molecular We do not have direct
myeloperoxidase, the chlorination
due
any 02-m formed)
radical
releases
02-’
Acknowledoment: and Engineering
myeloperoxidase
Thus, no reaction
for the formation
to the interaction
of the autoxidation
was suggested
(16) which
adverse
leads to further
reactions.
hydrogen
This work was supported Research Council of Canada.
by operating
enzyme
which
conditions.
of ferro-myeloperoxidase,
however
c. products
of penicillamine
explanation
and the reducing Similarly,
peroxide
two possible
under anaerobic
as a possible acceptor
c is still
with the 02-m formed;
II and Ill form. While these two intermediates
II can act as a one-electron of mediating
reacts
was observed
agent for cytochrome
(which
cytochrome
to form the ferrous
is a reducing
reaction capable
reduce
to form) or in the
III could form through
then myeloperoxidase
evidence
both compounds
effect (6)) compound free
oxygen.
spectral
we show that penicillamine Thus,
autoxidizes
of acting as reducing
no 02-m is expected
It is also evident from these results that compound pathways:
donor is shown by its
are inactive
7. 8. 9. IO. 11. 12. 13. 14. 15. 16.
the decay
becomes
of compound
a III
production.
grant A1248
from the Natural Sciences
Feltkamp, T.E.W. (1979). Stand. J. Rheum. (suppl) 28. Chwalinska-Sadowska, H., and Baum, J. (1976) J. Clin Invest. 58, 871-879. Binderup, L., and Arrigoni-Martelli, E. (1979) Biochem. Pharmacol. 28, 189-192. Maini, R. N., and Berry, H. (1981) Clin. Pharmacol.Ther. Ser. 1, l-310. Matheson, N. R. (1982) Biochem. Biophys. Res. Comm. 108, 259-265. Cuperus, R. A., Muijsers, A. O., and Wever, R. (1983) Biochim. Biophys. Acta 749, 18-23. Stein, H. B., Patterson, A. C., Offer, R. C., Atkins, C. J., Teufel, A., and Robinson, H. S. (1980) Ann. Intern. Med. 92, 24-29. Davis, J. C., and Averill, B. A. (1981) J. Biol. Chem. 256, 5992-5996. Davis, J. C., and Averill, B. A. (1984) Inorg. Chim. Acta 93, L49-L51. Ikeda-Saito, M. (1985) J. Biol. Chem. 260, 11688-11696. Agner, K. (1958) Acta Chem. Stand. 12, 89-94. Briggs, R. G., and Fee, J. D. (1978) Biochim. Biophys. Acta 537, 86-99. Samejima, T., and Yang, J. T. (1963) J. Biol. Chem. 238, 3256-3261. Nelson, D. P., and Kiesow, L. A. (1972) Anal. Biochem. 49, 474-478. Saetre, R. and Rabenstein, D. L. (1978) Anal. Chem. 50, 276-280. Metodiewa, D., and Dunford, H. B. (1989) Arch. Biochem. Biophys. 272, 245-253.
1163
in
for its therapeutic substrate
REFERENCES 1. 2. 3. 4. 5. 6.
with